newsfilter
← Earnings
Earnings Releases·

Sight Sciences — Third Quarter 2026 Earnings Summary

Sight Sciences reported third-quarter 2026 revenue of $24.9 million, representing a 25% increase from the prior year period. The company achieved record revenue of $3.9 million for its Interventional Dry Eye segment, while Interventional Glaucoma revenue grew 7% to $21.0 million. Net loss for the quarter narrowed to $6.8 million, and cash usage decreased by 74% to $2.4 million compared to the same period in 2025. Sight Sciences raised its full-year 2026 revenue guidance to a range of $92 million to $93 million, driven by strong growth in both its glaucoma and dry eye product lines.

Company
SIGHT SCIENCES INC
Sector
Healthcare
Industry
Medical Devices